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The pathological effects of smoking are re-
lated to the duration of exposure (number of 
years) and its intensity (average number of 
cigarettes per day) [8]. It is estimated that 
for smokers the risk of developing broncho-
pulmonary pathologies ranges from 20 to 
50%, depending on exposure and intensity, 
compared to a 10-15% risk – thus limited, 
although not equal to zero – in non-smokers 
[6]. In addition, for this disease category, it 
has been shown that smoking accelerates the 
progression of the disease [9,10].
Giving up this addiction has beneficial ef-
fects on the health of patients. The results of 
a literature review show that – in coronary 
patients – quitting smoking reduces the risk 
of mortality by 36% and the risk of infarction 
by 32% [11].
Keeping the smoking phenomenon under 
control is a priority also because of its eco-
nomic consequences. A European Commis-
sion study shows that, in 2000, direct health 
IntroductIon
The promotion of smoking cessation is a 
worldwide Public Health priority, since to-
bacco addiction represents one of the major 
risk factors in the development of neoplastic, 
cardiovascular and respiratory diseases.
According to World Health Organization 
(WHO) data, tobacco smoke kills 5 million 
people per year worldwide and is responsible 
for 1 death out of 10 among the adult popula-
tion. The WHO also estimates that about half 
of regular smokers are destined to die prema-
turely, due to tobacco consumption [1], and 
similar values also emerge from studies con-
ducted on individual Countries [2].
Tobacco consumption increases the risk of 
cardiovascular (CVD) [3,4] and bronchopul-
monary diseases (COPD – chronic obstruc-
tive pulmonary disease) [5,6], as well as be-
ing the main cause of some types of cancer. It 
is also a risk factor for several chronic condi-
tions, including type 2 diabetes [7].
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INTRODUCTION: The promotion of smoking cessation is a worldwide Public Health priority.
OBJECTIVE: To estimate the budget impact on the Italian National Health Service (NHS) of the access to reimbursement 
of varenicline for the treatment of high risk patients with bronchopulmonary, diabetic and cardiovascular diseases.
METHODS: A closed-group Markov model was developed in order to compare the costs incurred by the NHS to promote 
smoking cessation with cessation-related savings, using an alternative scenario in which aids to cessation are not reim-
bursed by the NHS. The analysis was conducted over a 5-year time horizon, in the perspective of the Italian NHS. Efficacy 
was expressed in terms of smoke abstinence for at least one year, and data was derived from clinical trials; the savings 
associated with smoking cessation were derived from cost-of-illness studies.
RESULTS: The results show how costs would concentrate in the first year: they are estimated at € 200.6 million, of which 
€ 162.4 million for drug therapy and € 38.2 million for counseling. Average annual savings over the first five years are 
estimated at € 77.7 million, with a cumulative net impact at 5 years of € -188.0 million (cost-saving). The analysis appears 
to be robust: sensitivity analyses show that the covering of initial costs occurs in any case between the third and fourth year, 
and that the treatment remains cost-saving at 5 years.
CONCLUSIONS: The financial impact on the Italian NHS of the reimbursement of varenicline for the treatment of high 
risk smoking population would be a sustainable healthcare policy, resulting in cost savings starting from the fourth year. 
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The model
The model compares the costs incurred to 
promote smoking cessation and the cessa-
tion-related savings, using an alternative sce-
nario in which aids to cessation are not reim-
bursed by the NHS.
The analysis was conducted over a 5-year 
time horizon, in the perspective of the Italian 
NHS. Given the short time horizon consid-
ered, savings and costs were not discounted.
The model has a closed-group Markovian 
structure; in other words, the smokers cohort 
is considered and followed over time, with-
out considering new entrances in the smoker 
status (Figure 1).
The Markov model includes the smoker sta-
tus (naïve, and due to ineffectiveness of the 
treatment or to relapse) and the non-smoker 
status. The model does not include the esti-
mate of the mortality rate of smokers since, 
over the 5-year time horizon adopted, the 
number of deaths would be extremely low 
and therefore would not substantially affect 
the results of the model.
Treatment eligible population
The prevalent Italian population with COPD, 
diabetes, and CVD – who stated its intention 
to stop smoking – was considered. This pop-
ulation was offered both a pharmacological 
support, with varenicline, and a counseling 
service.
For the estimate of prevalent cases, the data 
of the National Statistics Institute (ISTAT) 
– collected during the Statistical Survey 
on the Health Conditions of the Population 
and the Resort to Health Services were used 
[14]. The survey reference period are the 12 
months from July 2012 to June 2013.
The sampling design has a general structure 
that resembles that of the sampling patterns 
of most household surveys, that is, a multi-
stage, district-family design, with stratifica-
tion of the Districts. In the reference period, 
the sample involved 60,368 families, for a 
total number of subjects equal to 119,073. 
As for tobacco addiction, the survey was 
conducted on the population starting from 
14 years of age, which in 2013 amounted to 
52,352,094 people [15].
People who declare to be suffering from 
COPD or emphysema are just over 2,225,000, 
of whom over 544,611 are smokers (Table 
I). As for diabetes, over 3.4 million people 
stated to be suffering from it, with a preva-
lence of 65.1 out of 1,000 inhabitants. Of 
these, 483,223 are smokers (Table I). Finally, 
as for CVD, namely AMI (acute myocardial 
infarction), angina pectoris and stroke, there 
are a total of 2,682,964 individuals, of whom 
333,119 are smokers.Figure 1. Markov model structure
costs for the damage caused by smoking af-
fected the GDP of the various Countries by 
1.04 to 1.39% [12].
In Italy, as in most Western Countries, sev-
eral tobacco control measures have been 
introduced in the last decades, both of the 
educational (e.g. campaigns for the promo-
tion of good lifestyles) and deterring type 
(e.g. ban on smoking in public places). These 
policies yielded significant results: according 
to ISTAT data, from 2001 to 2015 the pro-
portion of smokers dropped from 23.7% to 
19.6%, with a significantly higher decrease 
(from 31% to 24.6%) among men – who 
started from a very high prevalence – com-
pared to women (from 16.9% to 15.0%).
The prevalence of smokers remains, how-
ever, still too high: according to OECD data, 
Italy is – among the EU15 Countries – sixth 
in terms of amount of smokers, after Greece, 
Austria, Spain, France and Germany [13].
In addition to the enhancement of the afore-
mentioned approaches, pharmacological 
treatments are available to help the smoking 
cessation.
The aim of this analysis is to estimate the 
budget impact on the Italian NHS resulting 
from the access to reimbursement of var-
enicline for the treatment of patients with 
COPD, diabetes and CVD.
MAterIAls And Methods
Varenicline is a partial agonist of the a4b2 re-
ceptors, and exerts a strong antagonistic ac-
tion against nicotine at the level of the same 
receptors, as well as a partial agonist action, 
that occurs with a lower release of dopamine 
compared to nicotine.
Specifically, by acting nicotine-like at cere-
bral level, it is able to reduce the desire for 
cigarettes, thus helping some patients quit 
smoking.
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Based on the findings of Sicras-Mainar [21] 
in a cohort of Spanish diabetic patients, a cost 
of € 3,637.6 and € 2,864.0 is estimated for the 
smoking and the no longer smoking popula-
tion, respectively, with an annual saving per 
cessation of € 774.0.
The annual cost per CVD patient was esti-
mated based on the studies conducted by 
Fattore et al. [22] on stroke and Roggeri et 
al. [23] on myocardial infarction and angi-
na, which report values of € 11,747.0 and € 
11,464.0, respectively. An average cost was 
adopted, weighted on the number of the sam-
pled populations analyzed.
Using the findings of Sicras-Mainar [24] in a 
cohort of Spanish patients with CVD (angina 
pectoris, AMI, stroke and transient ischemic 
attack), an average annual cost of € 12,511.0 
and € 11,313.5 is estimated, for smokers and 
ex-smokers, respectively, with an annual sav-
ing per cessation of € 1,197.5.
The population eligible for treatment was 
estimated using the evidence available on 
the proportion of those who are planning to 
quit smoking with the help of the drug, net 
of those who would stop in any case [7]. Pa-
tients eligible for pharmacological treatment 
would therefore be 217,572 with COPD, 
154,535 with diabetes and 106,531 with 
CVD (Table I).
Treatment efficacy
Regarding the efficacy of the treatment (Ta-
ble II), the values adopted in this analysis 
are derived from the literature [7]. In par-
ticular, efficacy at week 52 of treatment was 
assumed to be 18.6% for COPD, 20.0% for 
diabetes and 19.2% for CVD [7]. The meta-
analysis carried out by Hoogendoorn et al. 
[16] showed that the 12-months smoking ab-
stinence rate in patients with COPD who fol-
lowed the usual care, defined as the absence 
of any type of smoking cessation interven-
tion, was negligible (about 1%). The rate of 
relapses was assumed to be 3% per year [7] 
for the entire eligible population considered.
Costs
The price of the drug used for the calculation 
is € 339.31, equal to the cost (retail price in 
class A) of 12 weeks of treatment, as indi-
cated in the SPC [17]: one 0.5 mg tablet once 
daily for 3 days, then one 0.5 mg tablet twice 
daily for 4 days and finally one 1.0 mg tab-
let twice daily for the remaining 11 weeks of 
treatment (Table III).
As for the counseling service, 4 visits with 
a psychologist were assumed, for a total 
amount of € 79.84 (unit cost of the visit equal 
to € 19.96, as specified by the Italian National 
Tariff [18]) (Table III).
As for the estimate of the savings resulting 
from the cessations, this was done separately, 
for each disease branch1.
The average annual cost per COPD patient 
was assumed to be € 2,723.7 [19]; the estimate 
for the smoking and non-smoking population 
was carried out by adopting the savings ratio 
collected by Sicras-Mainar [6] from a cohort 
of Spanish patients with COPD specifically 
treated to promote smoking cessation, which 
highlighted a cost of € 3.775,4 per smoking pa-
tient and € 2,382.4 per no longer smoking pa-
tient, with an average annual saving per capita 
resulting from the cessation of € 1,393.0.
Through a similar procedure, patients with 
diabetes are assumed to have a mean annual 
cost per patient of € 2,898.0 [20].
1 Reduction in costs is related to the reduction in the number 
of visits and days of hospitalization between smoking and 
no longer smoking patients
COPD/
emphysema
Diabetes
aMi, angina, 
stroke
Total 2,225,039 3,406,477 2,682,964
Non-smokers 1,680,428 2,923,254 2,349,845
Smokers
 • % 24.48 14.19 12.42
 • n. 544,611 483,223 333,119
Smokers willing to quit [7]
 • % 39.95 31.98 31.98
 • n. 217,572 154,535 106,531
Table i. Smoker population > 14 years with COPD/emphysema, diabetes, or 
cardiovascular disease and patients eligible for pharmacological treatment
AMI = acute myocardial infarction; COPD = chronic obstructive pulmonary disease
input COPD Diabets CVD
Efficacy at week 52 (%) 18.60 20.00 19.20
Rate of relapses (%) 3.00 3.00 3.00
Table ii. Treatment efficacy [7]
COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease
Cost item input source
Drug cost (€) 339.31 Retail price in class A of 
12 weeks of treatment
Psychological visits
 • Unit cost (€) 19.96 [18]
 • n. 4.00 Assumption
 • Total cost (€) 79.84 -
Total cost of therapy (€) 419.15 -
Table iii. Costs of therapy
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first year (of which € 73.8 million for the drug 
and € 17.4 million for counseling); the cumu-
lative savings in the first five years would 
amount to € 209.1 million, with a savings 
of € 117.9 million for the NHS (Figure 2). 
Treatment of COPD patients becomes cost-
saving starting from the third year (Table IV 
and Figure 2).
Italian diabetic patients who smoke but are 
also willing to quit are 154,535; should the 
reimbursability of varenicline be recognized, 
the cost for the NHS would be € 64.8 million, 
all concentrated in the first year (of which € 
52.4 million for the drug and € 12.3 million for 
counseling); the cumulative savings achiev-
able in the first five years would amount to € 
88.7 million, with a savings of € 23.9 million 
for the NHS. Treatment of patients with dia-
betes becomes cost-saving starting from the 
fourth year (Table V and Figure 3).
Figure 2. Budget impact of varenicline in smokers with COPD
 Year 1 Year 2 Year 3 Year 4 Year 5
Additional costs (€) 91,195,343 - - - -
Savings (€) 0 -54,681,985 -53,041,525 -51,450,279 -49,906,771
Budget impact (€) 91,195,343 -54,681,985 -53,041,525 -51,450,279 -49,906,771
Cumulative budget impact (€) 91,195,343 36,513,359 -16,528,167 -67,978,446 -117,885,217
Table iV. Budget impact of varenicline in smokers with COPD
Figure 3. Budget impact of varenicline in smokers with diabetes
 Year 1 Year 2 Year 3 Year 4 Year 5
Additional costs (€) 64,773,226  - - - -
Savings (€) 0 -23,193,097 -22,497,304 -21,822,385 -21,167,714
Budget impact (€) 64,773,226 -23,193,097 -22,497,304 -21,822,385 -21,167,714
Cumulative budget impact (€) 64,773,226 41,580,129 19,082,824 -2,739,561 -23,907,275
Table V. Budget impact of varenicline in smokers with diabetes
sensitivity analysis
In order to evaluate the impact of the uncer-
tainty of the input parameters on the results 
obtained, a univariate sensitivity analysis 
was conducted, in which a variation of re-
lapses of ± 2%, a change in unit savings of ± 
10%, and a variation of the population treated 
of ± 10% were assumed.
results
Italian COPD patients who smoke but are 
also willing to quit are 217,572; should the 
reimbursability of varenicline be recognized 
for those who are planning to stop smoking 
with the aid of the drug, net of those who 
would stop in any case, the cost for the NHS 
would be € 91.2 million, concentrated in the 
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first year (of which € 73.8 million for the drug 
and € 17.4 million for counseling); the cumu-
lative savings in the first five years would 
amount to € 209.1 million, with a savings 
of € 117.9 million for the NHS (Figure 2). 
Treatment of COPD patients becomes cost-
saving starting from the third year (Table IV 
and Figure 2).
Italian diabetic patients who smoke but are 
also willing to quit are 154,535; should the 
reimbursability of varenicline be recognized, 
the cost for the NHS would be € 64.8 million, 
all concentrated in the first year (of which € 
52.4 million for the drug and € 12.3 million for 
counseling); the cumulative savings achiev-
able in the first five years would amount to € 
88.7 million, with a savings of € 23.9 million 
for the NHS. Treatment of patients with dia-
betes becomes cost-saving starting from the 
fourth year (Table V and Figure 3).
Figure 2. Budget impact of varenicline in smokers with COPD
 Year 1 Year 2 Year 3 Year 4 Year 5
Additional costs (€) 91,195,343 - - - -
Savings (€) 0 -54,681,985 -53,041,525 -51,450,279 -49,906,771
Budget impact (€) 91,195,343 -54,681,985 -53,041,525 -51,450,279 -49,906,771
Cumulative budget impact (€) 91,195,343 36,513,359 -16,528,167 -67,978,446 -117,885,217
Table iV. Budget impact of varenicline in smokers with COPD
Figure 3. Budget impact of varenicline in smokers with diabetes
 Year 1 Year 2 Year 3 Year 4 Year 5
Additional costs (€) 64,773,226  - - - -
Savings (€) 0 -23,193,097 -22,497,304 -21,822,385 -21,167,714
Budget impact (€) 64,773,226 -23,193,097 -22,497,304 -21,822,385 -21,167,714
Cumulative budget impact (€) 64,773,226 41,580,129 19,082,824 -2,739,561 -23,907,275
Table V. Budget impact of varenicline in smokers with diabetes
Italian patients with CVD who smoke but are 
also willing to quit are 106,531; should the 
reimbursability of varenicline be recognized, 
the cost for the NHS would be € 44.6 mil-
lion, concentrated in the first year (of which 
€ 36.1 million for pharmacotherapy and € 8.5 
for counseling); the cumulative savings in 
the first five years would amount to € 90.8 
million, with a saving of € 46.2 million for 
the NHS. Treatment of patients with CVD 
becomes cost-saving starting from the third 
year (Table VI and Figure 4).
sensitivity analysis
The reimbursement of varenicline remains 
constantly cost-saving starting from the 
third year of treatment, except where there 
is a 10% reduction in unit savings or a 10% 
increase in the population treated: in these 
cases the treatment becomes however cost-
Figure 4. Budget impact of varenicline in smokers with CVD
 Year 1 Year 2 Year 3 Year 4 Year 5
Additional costs (€) 44,652,660  - - - -
Savings (€) 0 -23,758,305 -23,045,555 -22,354,189 -21,683,563
Budget impact (€) 44,652,660 -23,758,305 -23,045,555 -22,354,189 -21,683,563
Cumulative budget impact (€) 44,652,660 20,894,355 -2,151,200 -24,505,389 -46,188,952
Table Vi. Budget impact of varenicline in smokers with CVD
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Kingdom, Greece and Italy, shows a cost per 
QALY gained at 52 weeks ranging from a 
minimum of € 4,478 for UK, up to a maxi-
mum of € 10,167 for Italy.
The 10-year extrapolation shows a decrease 
in the Incremental Cost-Effectiveness Ratio 
(ICER): in the short term (4-5 years) vareni-
cline is cost-effective adopting a willingness 
to pay (WTP) greater than € 30,000, while 
with a longer time horizon it becomes cost-
effective with a WTP greater than € 20,000.
A retrospective, multicentre, 24-month study 
[30] – conducted in a primary care setting 
in Spain on smokers followed by their GP – 
considered the varenicline therapy, with or 
without psychological support, and revealed 
that psychological support increases the ad-
herence to therapy, and therefore the success 
in quitting smoking.
Various studies have shown that, increasing 
the adherence to treatment, the public fund-
ing of antismoking drugs may be an essential 
condition for the effectiveness of the treat-
ment itself [31,32].
The Budget Impact deriving from the access 
to reimbursement of smoking cessation drugs, 
and in particular varenicline, was repeatedly 
analyzed: Taylor et al. [33] demonstrated the 
economic benefits deriving from the reim-
bursement of varenicline in the perspective 
of the UK NHS; in Spain Jiménez-Ruiz et al. 
[5] came to the same conclusions for COPD 
patients over a 5-year time horizon.
Cedillo et al. [7] – considering as target popu-
lation smokers with COPD, t2-DM or CVD, 
who represent a high-risk population both in 
terms of health and healthcare resources – es-
timate that varenicline reimbursement would 
be cost-saving from the third year.
This study, adopting a perspective similar to 
that of Cedillo et al. [7], evaluates the budget 
impacts of the access to reimbursement of 
varenicline, in the perspective of the Italian 
NHS.
Overall, a burden of € 200.6 million is esti-
mated for the first year – of which € 162.4 
million for drug therapy and € 38.2 million 
for counseling – which would be offset in 
the third year; from the fourth year, the treat-
ment is cost-saving, with a 5-year savings of 
€ 188.0 million.
It was assumed that all eligible patients were 
treated in the first year, which is an apparent-
ly unlikely supposition, because the burdens 
will certainly be divided over several years: 
for the purposes of the budget impact assess-
ment, it was decided to provide the most ex-
treme data, avoiding the introduction of ar-
bitrary hypotheses on the uptake of patients.
Based on the aforementioned assumptions 
and data, the financial impact (all concentrat-
saving starting from the fourth year. The tor-
nado diagram (Figure 5) reports the five-year 
savings achieved in the various simulations.
dIscussIon
Studies on the efficacy and cost-effectiveness 
of the pharmacological smoking cessation 
therapy, often associated with a motivational 
support, are relatively recent and show an 
evolution in terms of achievable goals.
The first studies, in fact, were carried out 
in order to evaluate the effectiveness of the 
pharmacological treatment: Cahill et al. 
[25], through a literature review, show the 
high rate of success (smoking abstinence) 
in healthy subjects undergoing varenicline 
therapy, compared with placebo and bupro-
pion. Similarly, other studies [26,27] show a 
44% cessation rate after 12 weeks of therapy, 
versus lower average values (17.6%) for pla-
cebo-treated patients.
Efficacy analyses on populations with con-
ditions for which smoking is an aggravating 
factor were subsequently published: a con-
trolled study [28] – conducted on a sample 
of 714 smokers with CVD from 15 different 
countries – evaluated the rate of success of 
varenicline (administered for 12 weeks) ver-
sus placebo, highlighting an average 12-week 
abstinence rate of 54.1% among the patients 
treated, versus 18.1% among the controls; the 
persistence of abstinence at one year remains 
higher in the varenicline group (19.2%) ver-
sus controls (7.2%).
The pharmacoeconomic aspect was exam-
ined in depth through an analysis carried out 
in four European Countries (Belgium, Spain, 
Portugal and Italy) by Wilson et al. [3]: based 
on the evidence highlighted by Rigotti et al. 
[28], the cost per QALY gained with the use 
of varenicline is estimated at € 6,120 for Bel-
gium, € 5,151 for Spain, € 5,357 for Portugal, 
and € 5,433 for Italy.
A study with a similar structure to those pre-
viously mentioned, conducted in patients 
with chronic obstructive pulmonary disease 
(COPD) [29] in Spain, Germany, United 
Figure 5. Results of the sensitivity analysis: the tornado diagram
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fourth year, and that the treatment remains in 
any case cost-saving at 5 years.
The perspective used is that of the Italian 
NHS, and therefore it does not take into ac-
count the indirect costs (benefits for society 
deriving from lower productivity losses) and 
the out-of-pocket direct costs incurred by 
families: the analysis can therefore be con-
sidered conservative.
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ed in the first year) is less than 1.85% of the 
Class A public pharmaceutical expenditure 
[34], and less than 0.002% of the national 
public health expenditure, without even con-
sidering any wholesale discounts.
conclusIons
The financial impact on the Italian NHS of 
the reimbursement of varenicline for the 
high-risk smoking population willing to stop 
would be a sustainable healthcare policy, re-
sulting cost-savings from the fourth year. In 
particular, it should be noted that the costs, 
that was estimated at € 200.6 million, would 
be concentrated in the first year. Average an-
nual savings over the first five years are esti-
mated at € 77.7 million, with a five-year sav-
ings of € 188.0 million.
Conclusions appear to be robust: sensitiv-
ity analyses show that the covering of initial 
costs occurs in any case between the third and 
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